Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- With New CV Drugs, Gilead Tests Its Commitment to Efficiency
- Gilead received some good news today with the results of a positive phase 3 study of its new high-blood pressure drug, darusentan. Combined with Gilead's purchase of CV Therapeutics to gain the chronic angina drug Ranexa, this marks a new push into the cardio-vascular area for a...
- Blog posts 2009-04-03
Additional Resources
- CV Therapeutics Begins Shipments of Ranexa to Wholesalers and Merck and Paratek Pharmaceuticals Sign Collaboration Agreement.
- M2 PRESSWIRE-13 March 2006-US Financial Network: CV Therapeutics Begins Shipments of Ranexa to Wholesalers and Merck and Paratek Pharmaceuticals Sign Collaboration AgreementC1994-2006 M2 COMMUNICATIONS LTD RDATE:13032006 City of Industry, CA - March 13, 2006 - Biotechnology industry news provided by...
- Research articles 2006-03-13
- CV Therapeutics Inc. Q4 2007 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions Your first question comes from the line of Jim Birchenough. Louis Lange Hi, Jim. Jim Birchenough - Lehman Brothers Hi, guys. Just a couple of questions, one on your cash burn guidance. You are already on a cash burn run rate for less $85 million...
- Earnings calls 2008-02-27
- Gilead Deal Gives CV Therapeutics CEO $8.4 Million Payday Despite Lack of Profits
- Gilead's $1.4 billion takeover of CV Therapeutics was a good deal for one man: CVT CEO Louis G. Lange, who picks up an $8.4 million change-of-control bonus in the pact, according to a CVT filing with the SEC. It's a particularly good deal considering that CVT hasn't...
- Blog posts 2009-03-13
- Quintiles Transnational.(Triangle)(CV Therapeutics Inc.)(Brief Article)
- DURHAM -- Drug researcher Quintiles Transnational sold the rights to Ranexa, a chronic-angina treatment in the final stages of U.S. Food and Drug Administration approval, back to Palo Alto, Calif.-based CV Therapeutics for 200,000 shares of ... DURHAM -- Drug researcher Quintiles Transnational sold the rights...
- Research articles 2003-09-01
- CV Therapeutics, Inc. Q2 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instruction. Your first question comes from the line of Jim Birchenough with Lehman Brothers. Jim Birchenough - Lehman Brothers. Guys, congratulations on the quarter. Louis Lange Thanks, Jim. Jim Birchenough - Lehman Brothers. So, just a question on the process with FDA right now around...
- Earnings calls 2008-07-31
- CV Therapeutics Inc. Q1 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions. Your first question comes from the line of Bret Holley with Oppenheimer & Co. Bret Holley - Oppenheimer & Co Congratulations on the approval. Louis Lange Thanks, Bret. Bret Holley - Oppenheimer & Co Hey, I just got a question about the relative timing of...
- Earnings calls 2008-04-25
- CV Therapeutics Q3 2007 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions. Your first question comes from the line of Mark Monane, with Needham. Mark Monane - Needham Thank you very much for taking my question, and for the thorough review of the busy quarter. Lou Lange Hi, Mark. Mark Monane - Needham A couple of questions....
- Earnings calls 2007-11-06
- CV Therapeutics, Inc. Q3 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator instructions Your first question is from the line of Jim Birchenough. Jim Birchenough – Barclays Capital Hi, guys, congratulations on the label expansion. Louis Lange Thank you. Jim Birchenough – Barclays Capital So, just a few questions. Number one, just wondering how you're...
- Earnings calls 2008-11-19
- Will CV Therapeutics Get a Higher Price from Astellas?
- Kirk Shinkle submits: Tokyo-based pharma company Astellas Pharma offered $1 billion in cash or $16 a share for CV Therapeutics CVTX, which makes small molecule cardiovascular drugs including angina treatment Ranexa. The deal is a 41 percent premium to CVTX's closing price, and shares promptly jumped today in expectation of...
- External links 2009-01-27
- Gilead Subpoena Will Have Investors Guessing: What's Wrong With the CVT Acquisition?
- Gilead's single-sentence announcement that it has received a subpoena regarding Ranexa from the Office of the Inspector General of HHS could be nothing or anything. One thing is for sure, securities class-action lawyers will be watching this very closely, as the subpoena comes just a few months after Gilead acquired...
- Blog posts 2009-08-17
- << Previous
- page 1 of 1
- Next >>
